Events

Join the Greater Intermountain Node on June 16, 2026 (12-1pm MST) for their next GIN on the Rocks webinar: Psychedelic-Assisted Interventions for Mental Health and Substance Use: Current Evidence and Emerging Directions Presenter: Yitong Xin, PhD Psychedelic-assisted interventions have gained significant scientific and public attention, yet many researchers and clinicians remain unfamiliar with the current state of the evidence. This presentation will provide an accessible overview of psychedelic science and emerging clinical evidence across depression, trauma, and substance use, with Dr. Xin highlighting her research program’s contributions across multiple populations and substances. The presentation concludes with a discussion of where the addiction research community can contribute. About the speaker: Yitong Xin, Ph.D., is an Assistant Professor at the College of Social Work, University of Utah. Her work focuses on clinical research at the intersection of mental health and substance use treatment, emphasizing harm reduction (e.g., psychedelic-assisted interventions) and strengths-based methodologies. Dr. Xin earned her Ph.D. from The Ohio State University, where she trained at the Center for Psychedelic Drug Research and Education. Join the Zoom: Meeting ID: 835 8472 5058 Passcode: ginotr

Join host Ohio Valley Node PI T. John Winhusen, PhD, this summer for the University of Cincinnati/UC Health Addiction Center’s webinar series! This series will highlight cutting-edge UC addiction research and UC-community collaborations focused on prevention and treatment. The second installment in the series will feature Victor Schneider, PhD, and Christian C. Garcia, PhD (both of U. Cincinnati) talking about heavy drinking in midlife and older adults. Register here.

Join the CTN Translation & Implementation SIG for their next meeting, July 21, 2026, 9-10am PT. Drs. Sabeeh Baig, Jeremiah Bertz, and Landhing Moran will describe the methods and findings from their comprehensive portfolio analysis of all studies within the CTN approved from 2000 through 2024. Their presentation will highlight scientific areas in the CTN portfolio, portfolio growth trends, and research impact through this period. The presentation will conclude with a discussion of the CTN's achievements and the strengths of its trial infrastructure. Read more about the speakers Contact Elena Rosenberg-Carlson at rosenbee@stanford.edu for the meeting link or to join the CTN T&I email list.

The Harm Reduction International Conference is convened by Harm Reduction International in a different city every two years. Over four days of presentations, workshops, films, networking events and more, the conference provides a dynamic forum to share the latest research and discussions on best practice in drug use, harm reduction and human rights and attracts a diverse group of over 1,000 delegates and speakers including front-line health workers, academics, researchers, policy makers, politicians, UN representatives, people who use drugs, sex workers and people working in the criminal legal system.

Join the Health Systems Node for this upcoming event at which Caitlin Ryus, MD, MPH, Assistant Professor in the Department of Emergency Medicine at Yale School of Medicine, will discuss a Connecticut-based study that links administrative data from homelessness services and electronic health records to examine the relationship between rapid rehousing and substance-related emergency department visits. Connect: Microsoft Teams. Meeting ID: 250 658 877 216 6 | Passcode: B8jq2m9A.

Join host Ohio Valley Node PI T. John Winhusen, PhD, this summer for the University of Cincinnati/UC Health Addiction Center’s webinar series! This series will highlight cutting-edge UC addiction research and UC-community collaborations focused on prevention and treatment. The third and final installment of this series will feature Corey J. Hayes, PharmD, PhD, MPH (U. Arkansas) and Daniel Bebo, MD (U. Cincinnati) talking about personalized medicine for opioid use disorder. Register here.

Join over a thousand fellow addiction professionals at the Sheraton Kansas City Hotel at Crown Center in Kansas City, MO, for the 2026 NAADAC Annual Conference (theme: Empower 2026). This immersive educational experience will provide you with addiction-specific CEs, fantastic networking opportunities, and the chance to learn about the latest advancements in the field. Join us in August and take part in interactive workshops, panel discussions, pre- and post-conference sessions, poster presentations, an exhibit hall, special events, networking opportunities, and so much more! Registration is now open!

Join the Health Systems Node for this upcoming session, in which Tessa Matson, PhD, MPH, Collaborative Scientist at Kaiser Permanente Washington Health Research Institute, will present findings from a CTN implementation trial on factors that distinguished clinics that successfully increased opioid use disorder treatment from those that did not. Connect: Microsoft Teams. Meeting ID: 250 658 877 216 6 | Passcode: B8jq2m9A.

The next CTN Quarterly Steering Committee Meeting is scheduled for Tuesday, September 15, 2026, from 1-3:30pm ET. The agenda includes: Join the meeting here

CME accreditation for providers pending; a certificate of attendance will be available for all attendees (in-person or virtual) Register here (for in-person and virtual attendance) | View program In a recent survey of Washington State healthcare providers about cannabis negative effects, 70% of respondents reported seeing cases of severe abdominal pain, nausea, retching, and relentless vomiting among people reporting heavy cannabis use. This cluster of symptoms is now recognized as Cannabinoid Hyperemesis Syndrome (CHS). As CHS becomes more visible in clinical settings, providers are left navigating care without clear understanding or guidance. At the same time, while 1 in 10 Washingtonians who consumed cannabis in the last year report vomiting and nausea due to their cannabis use2, many people remain skeptical that the condition exists at all, creating challenges for treatment, prevention and health education. To better understand these dynamics, we are making CHS the focus of this year’s ADAI Symposium. Join the University of Washington's Addictions, Drug & Alcohol Institute (home of the CTN Pacific NW Node) on September 18, 2026, to learn more about:   CHS prevalence among adolescents and adults in U.S. emergency departments CHS in Washington State CHS as a contested disease and implications for health communication CHS presentation, treatment, and management across settings Policy recommendations to prevent CHS increase Improving care for individuals with CHS

The Greater Southern California Node and its Pacific Southwest Addiction Technology Transfer Center (PSATTC) partners would like to invite you to Guam's 7th Annual Behavioral Behavioral Health & Addictions Virtual Conference. This FREE two-day virtual conference held in recognition of National Recovery Month will feature 4 plenary presentations and 4 breakout sessions, offering 8 concurrent workshop tracks. Whether you are looking to strengthen your clinical practice, learn about emerging trends, or discover innovative approaches to providing care, this conference offers valuable education and practical strategies to support your work. Sponsored by the Guam Behavioral Health and Wellness Center and the Pacific Southwest ATTC.

Join the Northeast Node for the next installment of their Science Series: Using AI and Passive Data to Improve Digital Assessment and Treatment of Substance Use and Mental Health Disorders. Presented by Nicholas C. Jacobson, PhD. Dr. Jacobson, PhD, is an Associate Professor of Biomedical Data Science and Psychiatry at Dartmouth's Geisel School of Medicine, where he directs the AI and Mental Health: Innovation in Technology Guided Healthcare (AIM HIGH) Laboratory. He has published over 130 peer-reviewed papers (H-index: 44), with a large portion focused on using passively collected smartphone and wearable sensor data to detect psychiatric disorders, measure symptom severity, and predict real-time changes in mental health. His work spans data from over 10,000 participants across 100+ countries. In this talk, he will cover how these digital phenotyping methods have been applied within the CTN through the D-TECT study (CTN-0084-A2), his lab's personalized digital therapeutics for co-occurring anxiety, depression, and substance use disorders, and the 6.5-year development of Therabot, a generative AI psychotherapy chatbot. Therabot was tested in the first randomized controlled trial of generative AI psychotherapy, published in the New England Journal of Medicine AI, where 210 participants showed large symptom reductions (d=0.63 to 0.90) and averaged over 6 hours of engagement across 24 days. He will close with implications for substance use treatment research.